Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 9, 2024: Nature Medicine
#2
JOURNAL ARTICLE
Molly Fisher Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, Pritha Sen, Nandini Samanta, Jessica Tantivit, Mazen Nasrallah, Leyre Zubiri, Neal P Smith, Alice Tirard, Swetha Ramesh, Benjamin Y Arnold, Linda T Nieman, Jonathan H Chen, Thomas Eisenhaure, Karin Pelka, Yuhui Song, Katherine H Xu, Vjola Jorgji, Christopher J Pinto, Tatyana Sharova, Rachel Glasser, PuiYee Chan, Ryan J Sullivan, Hamed Khalili, Dejan Juric, Genevieve M Boland, Michael Dougan, Nir Hacohen, Bo Li, Kerry L Reynolds, Alexandra-Chloé Villani
Immune checkpoint inhibitor (ICI) therapy has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). Little is understood about the pathogenic mechanisms driving irColitis, which does not readily occur in model organisms, such as mice. To define molecular drivers of irColitis, we used single-cell multi-omics to profile approximately 300,000 cells from the colon mucosa and blood of 13 patients with cancer who developed irColitis (nine on anti-PD-1 or anti-CTLA-4 monotherapy and four on dual ICI therapy; most patients had skin or lung cancer), eight controls on ICI therapy and eight healthy controls...
May 9, 2024: Nature Medicine
#3
Karen O'Leary
No abstract text is available yet for this article.
May 9, 2024: Nature Medicine
#4
JOURNAL ARTICLE
Lorenzo Subissi, James Richard Otieno, Nathalie Worp, Homa Attar Cohen, Bas B Oude Munnink, Laith J Abu-Raddad, Erik Alm, Amal Barakat, Wendy S Barclay, Jinal N Bhiman, Leon Caly, Meera Chand, Mark Chen, Ann Cullinane, Tulio de Oliveira, Christian Drosten, Julian Druce, Paul Effler, Ihab El Masry, Adama Faye, Elodie Ghedin, Rebecca Grant, Bart L Haagmans, Christian Happi, Belinda L Herring, Emma B Hodcroft, Juniorcaius Ikejezie, Victoria Katawera, Zyleen Alnashir Kassamali, Yee-Sin Leo, Gabriel M Leung, Rebecca J Kondor, Marco Marklewitz, Jairo Mendez-Rico, Nada M Melhem, Vincent Munster, Karen Nahapetyan, Dhamari Naindoo, Djin-Ye Oh, Thomas P Peacock, Malik Peiris, Zhibin Peng, Leo L M Poon, Andrew Rambaut, Senjuti Saha, Yinzhong Shen, Marilda M Siqueira, Erik Volz, Sofonias K Tessema, Volker Thiel, Henda Triki, Sylvie van der Werf, Karin von Eije, Jane Cunningham, Marion P G Koopmans, Anne von Gottberg, Anurag Agrawal, Maria D Van Kerkhove
No abstract text is available yet for this article.
May 8, 2024: Nature Medicine
#5
JOURNAL ARTICLE
Johanna I Westbrook, Nasir Wabe, Magdalena Z Raban
No abstract text is available yet for this article.
May 8, 2024: Nature Medicine
#6
JOURNAL ARTICLE
Frances Humby, Bruce Kirkham, Leonie Taams
No abstract text is available yet for this article.
May 8, 2024: Nature Medicine
#7
JOURNAL ARTICLE
Rafael Dal-Ré, Arthur L Caplan, Søren Holm, Reecha Sofat, Richard Stephens
No abstract text is available yet for this article.
May 8, 2024: Nature Medicine
#8
JOURNAL ARTICLE
Kate M Bermingham, Inbar Linenberg, Lorenzo Polidori, Francesco Asnicar, Alberto Arrè, Jonathan Wolf, Fatema Badri, Hannah Bernard, Joan Capdevila, William J Bulsiewicz, Christopher D Gardner, Jose M Ordovas, Richard Davies, George Hadjigeorgiou, Wendy L Hall, Linda M Delahanty, Ana M Valdes, Nicola Segata, Tim D Spector, Sarah E Berry
Large variability exists in people's responses to foods. However, the efficacy of personalized dietary advice for health remains understudied. We compared a personalized dietary program (PDP) versus general advice (control) on cardiometabolic health using a randomized clinical trial. The PDP used food characteristics, individual postprandial glucose and triglyceride (TG) responses to foods, microbiomes and health history, to produce personalized food scores in an 18-week app-based program. The control group received standard care dietary advice (US Department of Agriculture Guidelines for Americans, 2020-2025) using online resources, check-ins, video lessons and a leaflet...
May 8, 2024: Nature Medicine
#9
Sylvanus Toikumo, Rachel Vickers-Smith, Zeal Jinwala, Heng Xu, Divya Saini, Emily E Hartwell, Mirko Pavicic, Kyle A Sullivan, Ke Xu, Daniel A Jacobson, Joel Gelernter, Christopher T Rentsch, Eli Stahl, Martin Cheatle, Hang Zhou, Stephen G Waxman, Amy C Justice, Rachel L Kember, Henry R Kranzler
No abstract text is available yet for this article.
May 7, 2024: Nature Medicine
#10
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 7, 2024: Nature Medicine
#11
Paul Webster
No abstract text is available yet for this article.
May 7, 2024: Nature Medicine
#12
JOURNAL ARTICLE
Toru Kondo, Pardeep S Jhund, Samvel B Gasparyan, Mingming Yang, Brian L Claggett, Finnian R McCausland, Paolo Tolomeo, Muthiah Vadagunathan, Hiddo J L Heerspink, Scott D Solomon, John J V McMurray
Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the combination of time-to-event and longitudinal measurements and taking into account the clinical importance of the components of composite outcomes, as well as their relative timing. We examined this approach in a post hoc analysis of two trials that compared dapagliflozin to placebo in patients with heart failure and reduced ejection fraction (DAPA-HF) and mildly reduced or preserved ejection fraction (DELIVER)...
May 6, 2024: Nature Medicine
#13
JOURNAL ARTICLE
Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1-FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations). Secondary end points were progression-free survival, duration of response and overall survival in cohorts A and B, and safety...
May 6, 2024: Nature Medicine
#14
JOURNAL ARTICLE
Juan Fortea, Jordi Pegueroles, Daniel Alcolea, Olivia Belbin, Oriol Dols-Icardo, Lídia Vaqué-Alcázar, Laura Videla, Juan Domingo Gispert, Marc Suárez-Calvet, Sterling C Johnson, Reisa Sperling, Alexandre Bejanin, Alberto Lleó, Víctor Montal
This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes...
May 6, 2024: Nature Medicine
#15
JOURNAL ARTICLE
Qin Xu, Zherui Liang, Yadong Huang
No abstract text is available yet for this article.
May 6, 2024: Nature Medicine
#16
JOURNAL ARTICLE
Priya Prahalad, David Scheinker, Manisha Desai, Victoria Y Ding, Franziska K Bishop, Ming Yeh Lee, Johannes Ferstad, Dessi P Zaharieva, Ananta Addala, Ramesh Johari, Korey Hood, David M Maahs
Few young people with type 1 diabetes (T1D) meet glucose targets. Continuous glucose monitoring improves glycemia, but access is not equitable. We prospectively assessed the impact of a systematic and equitable digital-health-team-based care program implementing tighter glucose targets (HbA1c < 7%), early technology use (continuous glucose monitoring starts <1 month after diagnosis) and remote patient monitoring on glycemia in young people with newly diagnosed T1D enrolled in the Teamwork, Targets, Technology, and Tight Control (4T Study 1)...
May 3, 2024: Nature Medicine
#17
JOURNAL ARTICLE
Rima Arnaout
No abstract text is available yet for this article.
May 1, 2024: Nature Medicine
#18
JOURNAL ARTICLE
Yangong Wang, Yiran Xu, Chongchen Zhou, Ye Cheng, Niu Qiao, Qing Shang, Lei Xia, Juan Song, Chao Gao, Yimeng Qiao, Xiaoli Zhang, Ming Li, Caiyun Ma, Yangyi Fan, Xirui Peng, Silin Wu, Nan Lv, Bingbing Li, Yanyan Sun, Bohao Zhang, Tongchuan Li, Hongwei Li, Jin Zhang, Yu Su, Qiaoli Li, Junying Yuan, Lei Liu, Andres Moreno-De-Luca, Alastair H MacLennan, Jozef Gecz, Dengna Zhu, Xiaoyang Wang, Changlian Zhu, Qinghe Xing
Cerebral palsy (CP) is the most common motor disability in children. To ascertain the role of major genetic variants in the etiology of CP, we conducted exome sequencing on a large-scale cohort with clinical manifestations of CP. The study cohort comprised 505 girls and 1,073 boys. Utilizing the current gold standard in genetic diagnostics, 387 of these 1,578 children (24.5%) received genetic diagnoses. We identified 412 pathogenic and likely pathogenic (P/LP) variants across 219 genes associated with neurodevelopmental disorders, and 59 P/LP copy number variants...
May 1, 2024: Nature Medicine
#19
JOURNAL ARTICLE
Raúl Y Tito, Sara Verbandt, Marta Aguirre Vazquez, Leo Lahti, Chloe Verspecht, Verónica Lloréns-Rico, Sara Vieira-Silva, Janine Arts, Gwen Falony, Evelien Dekker, Joke Reumers, Sabine Tejpar, Jeroen Raes
Despite substantial progress in cancer microbiome research, recognized confounders and advances in absolute microbiome quantification remain underused; this raises concerns regarding potential spurious associations. Here we study the fecal microbiota of 589 patients at different colorectal cancer (CRC) stages and compare observations with up to 15 published studies (4,439 patients and controls total). Using quantitative microbiome profiling based on 16S ribosomal RNA amplicon sequencing, combined with rigorous confounder control, we identified transit time, fecal calprotectin (intestinal inflammation) and body mass index as primary microbial covariates, superseding variance explained by CRC diagnostic groups...
April 30, 2024: Nature Medicine
#20
JOURNAL ARTICLE
Matthew Christensen, Milos Vukadinovic, Neal Yuan, David Ouyang
The development of robust artificial intelligence models for echocardiography has been limited by the availability of annotated clinical data. Here, to address this challenge and improve the performance of cardiac imaging models, we developed EchoCLIP, a vision-language foundation model for echocardiography, that learns the relationship between cardiac ultrasound images and the interpretations of expert cardiologists across a wide range of patients and indications for imaging. After training on 1,032,975 cardiac ultrasound videos and corresponding expert text, EchoCLIP performs well on a diverse range of benchmarks for cardiac image interpretation, despite not having been explicitly trained for individual interpretation tasks...
April 30, 2024: Nature Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
